Vibeke Vergote

Efficacy and Safety of Ibrutinib Combined with Standard First-Line Treatment or As Substitute for Autologous Stem Cell Transplantation in Younger Patients with Mantle Cell Lymphoma: Results from the Randomized Triangle Trial By the European MCL Network

Martin Dreyling, Jeanette K. Doorduijn, Eva Giné et al. · Blood · 2022 · 84 citations

Medicine, Oncology, Pharmacotherapy +14

Role of Autologous Stem Cell Transplantation in the Context of Ibrutinib-Containing First-Line Treatment in Younger Patients with Mantle Cell Lymphoma: Results from the Randomized Triangle Trial By the European MCL Network

Martin Dreyling, Jeanette K. Doorduijn, Eva Giné et al. · Blood · 2024 · 23 citations

Medicine, Hematology, Oncology +13

Role of interim and end of treatment positron emission tomography for response assessment and prediction of relapse in posttransplant lymphoproliferative disorder

Ciska-Anne Van Keerberghen, Karolien Goffin, Vibeke Vergote et al. · Acta Oncologica · 2019 · 14 citations · Full text

Medicine, Nuclear Medicine, Oncology +17

Characteristics and Outcome of Post-Transplant Lymphoproliferative Disorders After Solid Organ Transplantation: A Single Center Experience of 196 Patients Over 30 Years

Vibeke Vergote, Christophe M. Deroose, Steffen Fieuws et al. · Transplant International · 2022 · 14 citations · Full text

Medicine, Hematology, Pathology +13

[¹⁸F]FDG-PET/CT volumetric parameters can predict outcome in untreated mantle cell lymphoma

Vibeke Vergote, Gregor Verhoef, Ann Janssens et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2022 · 11 citations

Medicine, Oncology, Hematologic Oncology +16